Loading…
TScan Therapeutics, Inc. is projected to decline to $1.03 by 2027, a -6% move from its current price of $1.09. TCRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.03 | $1.09 | $1.16 | +0.03% |
| Jul 14 | $1.00 | $1.09 | $1.19 | +0.06% |
| Jul 15 | $0.9825 | $1.09 | $1.21 | +0.09% |
| Jul 16 | $0.9669 | $1.09 | $1.23 | +0.12% |
| Jul 17 | $0.9535 | $1.09 | $1.25 | +0.15% |
| Jul 18 | $0.9416 | $1.09 | $1.27 | +0.18% |
| Jul 19 | $0.9307 | $1.09 | $1.28 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9307 | $1.09 | $1.28 | +0.21% |
| Week 2 | $0.8728 | $1.09 | $1.37 | +0.41% |
| Week 3 | $0.8313 | $1.10 | $1.45 | +0.62% |
| Week 4 | $0.798 | $1.10 | $1.51 | +0.83% |
| Week 5 | $0.77 | $1.10 | $1.58 | +1.04% |
| Week 6 | $0.7457 | $1.10 | $1.63 | +1.25% |
| Week 7 | $0.7242 | $1.11 | $1.69 | +1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company that develops T cell receptor-engineered T cell (TCR-T) therapies for cancer in the United States. The lead product is TSC-101 for the treatment of AML, MDS, and ALL in patients undergoing allogeneic hematopoietic cell transplantation (HCT) and is in Phase I clinical trial, with the goal to eliminate residual disease and promote donor chimerism.
The company also develops TSC-102-A01 and TSC-102-A03 as allogeneic and donor-derived TCR-T therapy candidates targeting epitopes, and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) is currently trading at $1.06, placing it within a developing biotechnology segment focused on TCR-T therapies. The company has a market capitalization of $69.27M and is ranked 4423 by market cap, reflecting its niche position within the healthcare landscape.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 22.9% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 36.1% above — clearing it would confirm fresh momentum.
Key TCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.11 | Sell | $1.09 | Sell |
| MA 10 | $1.06 | Buy | $1.06 | Buy |
| MA 20 | $0.9774 | Buy | $1.02 | Buy |
| MA 50 | $1.04 | Buy | $1.03 | Buy |
| MA 100 | $1.07 | Buy | $1.08 | Buy |
| MA 200 | $1.21 | Sell | $1.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.71 | Neutral |
| Stoch RSI (14) | 53.53 | Neutral |
| CCI (20) | 91.39 | Neutral |
| Williams %R (14) | -40.48 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 18.35 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 59.52 | Neutral |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 58.52 | Neutral |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.15 | Sell |
| ADX (14) | 16.04 | Neutral |
| ATR (14) | 0.06 | Info |
The technical picture shows a bullish sentiment, with RSI14 at 50. The stock trades above the 50-day simple moving average of $1.04 and below the 200-day simple moving average of $1.22. Support is listed at $0.84 and resistance at $1.26, framing a near-term range that sits between those levels.
Over the last 30 days, the price has moved within a range from $0.7041 to $1.60.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.84 | $1.09 | $1.48 | 0% | Neutral | |
| $0.744 | $1.03 | $1.53 | -6% | Neutral | |
| $0.7397 | $1.08 | $1.72 | -1% | Neutral | |
| $0.842 | $1.30 | $2.17 | +19% | Neutral | |
| $1.07 | $1.73 | $3.00 | +59% | Bullish | |
| $1.04 | $1.76 | $3.17 | +62% | Bullish | |
| $1.03 | $1.82 | $3.38 | +67% | Bullish | |
| $0.9648 | $1.77 | $3.37 | +63% | Bullish | |
| $0.8219 | $1.57 | $3.06 | +44% | Bullish | |
| $0.9916 | $1.97 | $3.93 | +81% | Bullish | |
| $1.12 | $2.49 | $5.46 | +128% | Bullish | |
| $2.52 | $5.60 | $12.89 | +414% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.84 | $1.09 | $1.38 | +0.00% |
| August 2026 | $0.9687 | $1.17 | $1.48 | +7.64% |
| September 2026 | $0.9116 | $1.12 | $1.44 | -4.56% |
| October 2026 | $0.8698 | $1.08 | $1.42 | -3.41% |
| November 2026 | $0.892 | $1.12 | $1.49 | +3.62% |
| December 2026 | $0.8641 | $1.10 | $1.48 | -2.17% |
Click any year to see its month-by-month TCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TCRX price prediction for 2026 points to an average of $1.09 (low $0.84, high $1.48) — a potential gain of 0% on today's $1.09. Price action looks broadly range-bound.
In 2027, TCRX is projected to trade between $0.744 and $1.53, averaging $1.03 — a potential decline of -6% from today's $1.09. That is -6% versus the projected 2026 average. A consolidation phase looks the most probable path here.
TScan Therapeutics, Inc.'s 2028 outlook centres on $1.08, within a $0.7397 to $1.72 range. That is up +6% on the projected 2027 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2029, TCRX could reach as high as $2.17, with a base case around $1.30 and support toward $0.842 — roughly +19% from $1.09. A consolidation phase looks the most probable path here.
Expect TCRX to range from $1.07 to $3.00 through 2030. The $1.73 average target implies a +59% move from current prices. That is up +33% on the projected 2029 average. Momentum favours further upside here.
The TCRX price prediction for 2031 points to an average of $1.76 (low $1.04, high $3.17) — a potential gain of +62% on today's $1.09. Buyers look set to stay in control over this stretch.
In 2032, TCRX is projected to trade between $1.03 and $3.38, averaging $1.82 — a potential gain of +67% from today's $1.09. That is up +3% on the projected 2031 average. Momentum favours further upside here.
TScan Therapeutics, Inc.'s 2033 outlook centres on $1.77, within a $0.9648 to $3.37 range. That is -3% versus the projected 2032 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, TCRX could reach as high as $3.06, with a base case around $1.57 and support toward $0.8219 — roughly +44% from $1.09. Momentum favours further upside here.
Expect TCRX to range from $0.9916 to $3.93 through 2035. The $1.97 average target implies a +81% move from current prices. That is up +25% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The TCRX price prediction for 2040 points to an average of $2.49 (low $1.12, high $5.46) — a potential gain of +128% on today's $1.09. Momentum favours further upside here.
In 2050, TCRX is projected to trade between $2.52 and $12.89, averaging $5.60 — a potential gain of +414% from today's $1.09. That is up +125% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRX today (≈ 917.431193 TCRX) could be worth
$5,141.63
+$4,141.63 (+414%) by 2050 · US Dollar
Based on the average projected TCRX price of $5.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRXwould be worth at today's price.
$1,000 invested in TCRX on Jul 10, 2025 (≈ 543.478251 TCRX) would be worth
$592.39
-$407.61 (-40.8%) today · 0.59× · US Dollar
Based on a TCRX entry price of $1.84 vs. today's $1.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.06 | $1,028.3 | +2.8% |
| 1 month ago | $0.919 | $1,186.07 | +18.6% |
| 3 months ago | $1.05 | $1,038.1 | +3.8% |
| 6 months ago | $1.17 | $931.62 | -6.8% |
| 1 year ago | $1.84 | $592.39 | -40.8% |
| All time (5.0y) ago | $10.5 | $103.81 | -89.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRX forecast.
Our base-case forecast reaches $2.20 around 2040.
Implied market cap at $2.20: $134.36M
The multi-year forecast points to upside beyond the near term. In 2026 the average price is projected at $1.06 with a range from $0.84 to $1.43 and an average that year near flat to the current level. By 2030 the average price is forecast at $1.64 with a maximum of $2.86 and a minimum of $1.02, yielding a 55.2% ROI in that year.
The 2040 forecast shows an average price of $2.35 and a maximum of $5.15, with an ROI of 121.3%. By 2050, the average price is projected at $5.21 and the maximum at $11.98, delivering an ROI of 391.2%. The outlook remains bullish through 2031–2035 and beyond, but these figures are estimates and not guarantees—subject to clinical outcomes, regulatory developments, and market dynamics.
Tap a question to reveal the answer.
2030 average price is $1.64 with a max of $2.86 and a min of $1.02; projected ROI is 55.2%.
Forecasts show a progression to a higher average price in 2030 ($1.64) and notable ROIs in 2040 (121.3%) and 2050 (391.2%), but there are earlier years with negative or smaller returns (e.g., 2027 -6.7%, 2028 -1%), and these are estimates, not guarantees.
Yes in the forecasts: the 2040 max is $5.15 and the 2050 max is $11.98, with the 2030 max at $2.86.
Current price is $1.06 and market capitalization is $69.27M.
Healthcare.
TScan Therapeutics, Inc. Community Discussion
0Share your TScan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.